{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 464389928
<!-- Monoclonal antibody data -->
| type = mab
| mab_type = mab
| source = zu/o
| target = [[Fibroblast activation protein|FAP]]
<!-- Clinical data -->
| tradename =  
| pregnancy_AU =  
| pregnancy_US =  
| pregnancy_category =  
| legal_AU =  
| legal_CA =  
| legal_UK =  
| legal_US =  
| legal_status =  
| routes_of_administration =  
<!-- Pharmacokinetic data -->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  
<!-- Identifiers -->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 216669-97-5
| ATC_prefix = none
| ATC_suffix =  
| PubChem =  
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = none
<!-- Chemical data -->
| chemical_formula =  
| molecular_weight =  
}}

'''Sibrotuzumab''' is a [[humanized monoclonal antibody]] intended for the treatment of cancer. It binds to FAP<ref>{{cite journal|pmid=12738716|year=2003|last1=Scott|first1=AM|last2=Wiseman|last3=Welt|last4=Adjei|last5=Lee|last6=Hopkins|last7=Divgi|last8=Hanson|last9=Mitchell|title=A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer|volume=9|issue=5|pages=1639–47|journal=Clinical Cancer Research|first2=G|first3=S|first4=A|first5=FT|first6=W|first7=CR|first8=LH|first9=P|last10=Gansen|first10=D. N.|last11=Larson|first11=S. M.|last12=Ingle|first12=J. N.|last13=Hoffman|first13=E. W.|last14=Tanswell|first14=P|last15=Ritter|first15=G|last16=Cohen|first16=L. S.|last17=Bette|first17=P|last18=Arvay|first18=L|last19=Amelsberg|first19=A|last20=Vlock|first20=D|last21=Rettig|first21=W. J.|last22=Old|first22=L. J.|display-authors=8}}</ref><ref>{{cite journal|pmid=14707493|year=2004|last1=Kloft|first1=C|last2=Graefe|last3=Tanswell|last4=Scott|last5=Hofheinz|last6=Amelsberg|last7=Karlsson|title=Population pharmacokinetics of sibrotuzumab, a novel therapeutic monoclonal antibody, in cancer patients|volume=22|issue=1|pages=39–52|journal=Investigational new drugs|doi=10.1023/B:DRUG.0000006173.72210.1c|first2=EU|first3=P|first4=AM|first5=R|first6=A|first7=MO}}</ref>

In 2003 it failed a phase II clinical trial for metastatic [[colorectal cancer]].<ref name=RDH2003>{{cite journal | pmid = 12624517 | doi=10.1159/000069863 | volume=26 | title=Stromal antigen targeting by a humanised monoclonal antibody: an early phase II trial of sibrotuzumab in patients with metastatic colorectal cancer | journal=Onkologie | pages=44–8 | last1 = Hofheinz | first1 = RD | last2 = al-Batran | first2 = SE | last3 = Hartmann | first3 = F | last4 = Hartung | first4 = G | last5 = Jäger | first5 = D | last6 = Renner | first6 = C | last7 = Tanswell | first7 = P | last8 = Kunz | first8 = U | last9 = Amelsberg | first9 = A | last10 = Kuthan | first10 = H | last11 = Stehle | first11 = G}}</ref>

==References==
{{reflist}}

{{Monoclonals for tumors}}

[[Category:Monoclonal antibodies for tumors]]


{{monoclonal-antibody-stub}}
{{antineoplastic-drug-stub}}